USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

USA In a shock move, Joe Biden’s administration looks set to support a waiver on intellectual property (IP) protections for COVID-19 vaccines.   The decision – which comes amid worrying situations in India and other counties and increasing concern that vaccine-resistant strains of COVID could undermine a global recovery – has…

Mexico While Mexico struggles with its COVID-19 vaccination campaign, residents of the country’s northern states have begun flying to the United States in search of a shot. Fearful of “fake vaccines” in their home country, some Mexicans are risking their tourism visas, and in some cases their lives, to be inoculated…

USA PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower US patients’ out-of-pocket spending and continue to drive innovation.   By bringing an end to the pandemic and lowering out-of-pocket…

USA With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National Organization for Rare Disorders (NORD), is making a push to put the spotlight on the limited access to diagnosis, treatment and care suffered by rare disease…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

USA Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan therapies in Europe, here we move to the world’s biggest biopharmaceutical market and R&D hub, shining the spotlight on five of the most important and innovative rare-disease start-ups in the USA.   The US…

USA Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required for novel therapies, why cost effectiveness considerations are on the rise, and the impact of the drug policy environment on payer sentiments.   The US reimbursement landscape…

USA Hours after President Biden was inaugurated on Tuesday 19th January 2021, Dr Janet Woodcock was named as acting commissioner for the Food and Drugs Administration (FDA). “The FDA’s public health work is more critical than ever as we continue to fight this global pandemic… The American people can be certain…

Norway Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare success story. CEO Dan Schneider explains how the company was able to action a more effective global commercial strategy and carve out a niche in the relatively uncrowded oncology drug-device combination market.   Despite its technology being…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and biosimilar drugs in the USA.   AAM’s 2020 access and savings report documenting the savings generated by generic prescription drugs once again trumpets the value proposition of generic and…